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Abstract
The Loeys–Dietz syndrome (LDS) is a connective tissue disorder affecting the cardiovascular,
skeletal, and ocular system. Most typically, LDS patients present with aortic aneurysms and
arterial tortuosity, hypertelorism, and bifid/broad uvula or cleft palate. Initially, mutations in
transforming growth factor-𝛽 (TGF-𝛽) receptors (TGFBR1 and TGFBR2) were described to cause
LDS, hereby leading to impaired TGF-𝛽 signaling.More recently, TGF-𝛽 ligands, TGFB2 and TGFB3,
as well as intracellular downstream effectors of the TGF-𝛽 pathway, SMAD2 and SMAD3, were
shown to be involved in LDS. This emphasizes the role of disturbed TGF-𝛽 signaling in LDS
pathogenesis. Since most literature so far has focused on TGFBR1/2, we provide a comprehensive
review on the known and some novel TGFB2/3 and SMAD2/3 mutations. For TGFB2 and SMAD3,
the clinical manifestations, both of the patients previously described in the literature and our
newly reported patients, are summarized in detail. This clearly indicates that LDS concerns a dis-
orderwith a broad phenotypical spectrum that is still emerging asmore patients will be identified.
All mutations described here are present in the corresponding LeidenOpen Variant Database.
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1 BACKGROUND
The Loeys–Dietz syndrome (LDS, MIM# 609192, 610168, 613795,
614816, 615582) is an autosomal dominant connective tissue disor-
der with widespread systemic involvement. In 2005, Loeys and Dietz
were the first to describe this disorder, which is—in its most typical
presentation—characterized by vascular tortuosity and aneurysm in
association with craniofacial and skeletal manifestations (Loeys et al.,
2005; Loeys et al., 2006). On the one hand, LDS shows significant
clinical overlap with Marfan syndrome (MFS, MIM# 154700), with
vascular and skeletal features including aortic root aneurysm, arachn-
odactyly, scoliosis, and pectus deformity. On the other hand, a clear
distinction between LDS and MFS can be made based on typical LDS
findings such as widespread aortic/arterial aneurysm and tortuosity,
club foot, craniosynostosis, hypertelorism, and bifid/broad uvula or
cleft palate. Other LDS-specific features can include cervical spine
malformation and/or instability, translucent skin with easy bruising
and dystrophic scars, severe allergic tendency, and bowel inflamma-
tion including eosinophilic esophagitis/gastritis and/or inflammatory
bowel disease. Soon after the initial description, the phenotypic
spectrum was expanded to less syndromic presentations, including
those that overlap with vascular Ehlers–Danlos syndrome (Loeys
et al., 2005; Loeys et al., 2006). Mutations in the genes encoding the
transforming growth factor 𝛽 (TGF-𝛽) receptor I (TGFBR1) and TGF-𝛽
receptor II (TGFBR2) subunits were the first reported genetic causes
of LDS. More recently, mutations in four additional genes, namely the
mothers against decapentaplegic homolog 2 and 3 (SMAD2/3) and the
TGF-𝛽 2 and 3 ligand (TGFB2/3), have been shown to cause an LDS-like
phenotype (Bertoli-Avella et al., 2015; Boileau et al., 2012; Lindsay
et al., 2012;Micha et al., 2015; van de Laar et al., 2011).
SMAD2 and SMAD3, located on the long arm of chromosome 18 and
15, span about 130 kb and consist of 11 and 9 exons, respectively. Both
the SMAD2and SMAD3proteins belong to the receptor-activated (R)-
SMAD family, intracellular effectors of the canonical TGF-𝛽 signaling
pathway. The activating ligands of this pathway include TGF-𝛽2 and
TGF-𝛽3, which are encoded by the TGFB2 and TGFB3 genes. These
genes include8 and7exons and are positionedon the long armof chro-
mosome 1 and 14, respectively. Including TGFBR1/2, all genes related
to LDS spectrum disorders are part of the TGF-𝛽 signaling pathway.
Additionally, fibrillin-1, which is encoded by the FBN1 gene and defi-
cient in MFS, binds to the large latent TGF-𝛽 complex and contributes
to TGF-𝛽 bioavailability and activation (Chaudhry et al., 2007; Isogai
et al., 2003; Neptune et al., 2003). This clearly highlights the key role
of the TGF-𝛽 pathway in the pathogenesis of aortic aneurysm devel-
opment in LDS and LDS-like disorders. However, the exact pathogenic
mechanisms remain controversial.
Initially, it was suggested that two types of LDS could be distin-
guished: patients with LDS type 1 (LDSI) displayed typical craniofacial
features, where LDS type 2 (LDSII) patients had more pronounced
cutaneous features. Recently, this classification was revised and these
LDS types are now thought to be part of a phenotypic spectrum of
disease. Therefore, LDS type 1 (LDS1) and LDS type 2 (LDS2) now
designate to the disease-responsible genes; TGFBR1 and TGFBR2,
respectively. Mutations in SMAD3 were initially described as the
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genetic cause of aneurysms-osteoarthritis syndrome, but because
of the many overlapping clinical features with LDS, including hyper-
telorism, bifid uvula, arterial tortuosity, andwidespread and aggressive
aneurysms, it is now also classified as LDS type 3 (LDS3) (MacCarrick
et al., 2014). Similarly, patients with mutations in TGFB2 share clinical
manifestations with LDS, and are for this reason now diagnosed with
LDS type 4 (LDS4). More recently, patients with mutations in SMAD2
and TGFB3 (LDS5) were also shown to present with LDS-like features
(Bertoli-Avella et al., 2015;Micha et al., 2015). It is thus suggested that
a mutation in any of these six genes in combination with the presence
of arterial aneurysm or dissection should be sufficient for the diagno-
sis of LDS (MacCarrick et al., 2014). Since most literature so far has
focused on LDS1 and LDS2, this review will highlight known and novel
SMAD2/3 and TGFB2/3 mutations and will summarize and compare
the clinical features of affected individuals with those reported in the
literature.
2 VARIANTS
Each published mutation was checked for accuracy and compared
to the respective wild-type reference sequence. When a differ-
ent reference sequence was used, nucleotide and codon numbers
were converted so their annotation matched with reference tran-
scripts: NM_001135599.2 for TGFB2, NM_003239.3 for TGFB3,
NM_005901.5 for SMAD2 and NM_005902.3 for SMAD3. The A
nucleotide of the translation initiation codon (ATG) was designated
as position +1. All variants are submitted to the corresponding
Leiden Open Variant Database (LOVD) (Fokkema et al., 2011)
http://143.169.238.105/LOVD/genes/TGFB2; http://143.169.238.
105/LOVD/genes/TGFB3; http://143.169.238.105/LOVD/genes/SMA
D2; http://143.169.238.105/LOVD/genes/SMAD3).
We report 7, 67, 30, and 15 different variants for SMAD2, SMAD3,
TGFB2, and TGFB3, respectively (Tables 1, 2, and 3 and Figures 1 and
2). These variants were either published as full article cited in PubMed
or newly identified in this study. We did not include variants from
abstracts (without full article) or the ClinVar database since little or
no clinical information is available on these individuals. Except for the
five variants listed in Table 4, these mutations are not found in the
ExAC database (http://exac.broadinstitute.org/; accessed April 2017).
To obtain an indication on the pathogenicity, all variants are classified
according to the ACMG guidelines (Suppl. Table S1) (Richards et al.,
2015).
For SMAD3, 40 variants were previously reported (Aubart et al.,
2014; Berthet, Hanna, Giraud, & Soubrier, 2015; Blinc et al., 2015;
Burke, Shalhub, & Starnes, 2015; Campens et al., 2015; Courtois
et al., 2017; Fitzgerald, Bhat, Conard, Hyland, & Pizarro, 2014; Garcia-
Bermudez,Moustafa, Barros-Membrilla, & Tizon-Marcos, 2017;Haller
et al., 2015; Hilhorst-Hofstee et al., 2013; Martens et al., 2013; Nev-
idomskyte et al., 2017; Proost et al., 2015; Regalado et al., 2011; Schu-
bert, Landis, Shikany, Hinton, & Ware, 2016; van de Laar et al., 2011;
van de Laar et al., 2012; van der Linde et al., 2012; Wischmeijer et al.,
2013; Yao et al., 2003; Ye et al., 2013; Zhang et al., 2015), whereas 38
probands were identified in this study, with 27 mutations that have
never been reported (Table 1 and Figure 1). These SMAD3 mutations
include 61% missense mutations, 23% frameshift mutations, 7% non-
sense mutations, 6% splice site mutations, and 3% whole or partial
gene deletions (Figure 3). The 30 TGFB2 mutations include 20 pre-
viously published pathogenic variants (Boileau et al., 2012; Campens
et al., 2015; Fontana et al., 2014; Gago-Diaz et al., 2014; Leutermann
et al., 2014; Lindsay et al., 2012; Renard et al., 2013; Ritelli et al., 2014;
Schubert et al., 2016) and 10 newly identified mutations (Table 2 and
Figure 2). In five new probands, previously reported TGFB2mutations
were identified. Newmutations include 30%missense mutations, 23%
frameshift mutations, 23% nonsense mutations, 14% whole or partial
gene deletions, 7% intragenic in-frame deletions, and 3% splice site
mutations (Figure 3). For SMAD2 and TGFB3, far fewer mutations have
been reported (Table 3) (Bertoli-Avella et al., 2015; Kuechler et al.,
2015; Matyas, Naef, Tollens, & Oexle, 2014; Micha et al., 2015; Rien-
hoff et al., 2013). In addition to the three previously reported SMAD2
mutations, we identified four new missense mutations, bringing the
total to sevenmissensemutations identified so far (Micha et al., 2015).
For TGFB3, we identified four additional probands with a mutation
that was previously published and four new mutations. The majority
of the TGFB3mutations consist of missense mutations (60%), whereas
20% are frameshift mutations, 13% are nonsensemutations, and 7%of
mutations affect a splice site.
No mutational hotspot is observed for SMAD2 and SMAD3 muta-
tions, but the majority (100% and 63%) reside in the MH2 domain, a
well conserved region responsible for the oligomerization of SMAD2
or SMAD3 with SMAD4 and subsequent Smad-dependent activation
of downstream transcription (Figure 1). For TGFB2, 23% of mutations
are located in the exons coding for the active TGF-𝛽2 cytokine and
28% reside in the RKKR-motif, a proteolytic cleavage site responsi-
ble for releasing mature TGF-𝛽2 from the latency-associated peptide
(LAP). Of the 17 mutations so far identified in the LAP domain of
TGFB2, 76% are nonsense or frameshift mutations, whereas 24% are
missense mutations. For TGFB3, 35% of mutations affect the RKKR-
motif. Remarkably, of the 23 currently known TGFB3mutations, three
substitute histidine for aspartic acid at amino acid position 263. This
arginine belongs to the RGD-motif that mediates binding to integrins
and subsequent integrin-mediated activation (release) of TGF𝛽3 from
its latent complex (Shi et al., 2011). Since all described patients with
this mutation originate from the same county, this might represent a
founder mutation (a hypothesis currently under investigation).
3 BIOLOGICAL RELEVANCE
For a long time, it was thought thatMFS, which is caused by mutations
in the fibrillin-1 gene, and related connective tissue disorders, was
caused by a pure structural deficiency of the extracellular matrix
(ECM), leading to tissue weakening of the aortic wall and resulting in
an increased risk of aneurysm progression and tear. Although some
manifestations of MFS, such as lens dislocation and aortic aneurysm
could be explained in this way, loss of structural tissue integrity could
not easily reconcile the skeletal overgrowth phenotype observed in
MFS patients or the low muscle mass and fat stores characteristic
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TABLE 1 Previously described and novel SMAD3 genemutations
Exon c-Notation p-Notation Domain Reference
Times
reported Effect
1 c.2T>C p.Met1Thr MH1 Haller et al. (2015) 1 Pathogenic
1 c.3G>A p.Met1Ile MH1 Fitzgerald et al. (2014) 1 Pathogenic
2 c.221G>A p.Arg74Gln MH1 Current study 2 Likely pathogenic
2 c.266G>A p.Cys89Tyr MH1 Zhang et al. (2015) 1 Pathogenic
2 c.269G>A p.Arg90His MH1 Current study 1 Likely pathogenic
2 c.281G> T p.Trp94Leu MH1 Blinc et al. (2015) 1 VUS
2 c.290T>G p.Leu97Arg MH1 Current study 1 VUS
2 c.300_301insAGGGCCG
GCAGGC
p.His101Argfs*14 MH1 Current study 1 Pathogenic
2 c.313delG p.Ala105Profs*11 MH1 van de Laar et al. (2012) 1 Pathogenic
2 c.335C> T p.Ala112Val MH1 (Regalado et al., 2011) 1 Likely pathogenic
2 c.370C>A p.Pro124Thr MH1 (Garcia-Bermudez et al.,
2017)
1 VUS
2 c.374A>G p.Tyr125Cys MH1 Current study 1 Likely pathogenic
2 c. 374A>C p.Tyr125Ser MH1 Current study 1 Likely pathogenic
3 c.401-6G>A p.Val134Aspfs*33 MH1 (Campens et al., 2015),
Current study
2 Pathogenic
3 c.401_405dup p.Pro136Phefs*52 MH1 (Berthet et al., 2015) 1 Pathogenic
3 c.455delC p.Pro152Hisfs*34 Linker (Courtois et al., 2017) 1 Pathogenic
3 c.511G> T p.Glu171* Linker Current study 1 Pathogenic
3 c.532+1G>C Linker Current study 1 Pathogenic
4 c.539_540insC p.Pro180Thrfs*7 Linker (van de Laar et al., 2012),
Current study
2 Pathogenic
4 c.546delT p.Gly183Alafs*3 Linker (Campens et al., 2015) 1 Pathogenic
4 c.584_585insTC p.Gln195Hisfs*3 Linker (Campens et al., 2015) 1 Pathogenic
5 c.652delA p.Asn218Thrfs*23 Linker (Regalado et al., 2011) 1 Pathogenic
6 c.668delC p.Pro223Glnfs*18 Linker (Aubart et al., 2014) 1 Pathogenic
6 c.715G>A p.Glu239Lys MH2 (Regalado et al., 2011),
(Campens et al., 2015)
4 Pathogeic
6 c.728G>C p.Arg243Pro MH2 Current study 1 Likely pathogenic
6 c.733G>A p.Gly245Arg MH2 (Aubart et al., 2014) 1 Likely pathogenic
6 c.741_742delAT p.Thr247Profs*61 MH2 (van de Laar et al., 2011) 1 Pathogenic
6 c.742T>C p.Phe248Leu MH2 (Aubart et al., 2014) 1 Likely pathogenic
6 c.748G>A p.Ala250Thr MH2 Current study 1 Likely pathogenic
6 c.762delC p.Met255* MH2 Current study 1 Pathogenic
6 c.772G>C p.Asp258His MH2 Current study 1 Likely pathogenic
6 c.782C> T p.Thr261Ile MH2 (van de Laar et al., 2011) 1 Pathogenic
6 c.788C> T p.Pro263Leu MH2 (van de Laar et al., 2012) 1 VUS
6 c.797C>A p.Ser266* MH2 (Haller et al., 2015) 1 Pathogenic
6 c.803G> T p.Arg268Leu MH2 (Schubert et al., 2016),
Current study
2 Likely pathogenic
6 c.836G>A p.Arg279Lys MH2 (Regalado et al., 2011) 2 Likely pathogenic
6 c.859C> T p.Arg287Trp MH2 (van de Laar et al., 2011),
(Campens et al., 2015)
2 Likely pathogenic
6 c.860G>A p.Arg287Gln MH2 (Aubart et al., 2014), Current
study
2 Likely pathogenic
6 c.861delG p.Arg288Aspfs*53 MH2 Current study 1 Pathogenic
7 c.862_871+1dupAGAC
ACATCGG
p.Arg292Aspfs*53 MH2 (Aubart et al., 2014) 1 Pathogenic
7 c.887T>C p.Leu296Pro MH2 (Campens et al., 2015) 1 Likely pathogenic
(Continues)
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TABLE 1 (Continued)
Exon c-Notation p-Notation Domain Reference
Times
reported Effect
7 c.988A>G p.Thr330Ala MH2 (Ye et al., 2013) 1 Likely pathogenic
7 c.1009+1G>A MH2 Current study 1 Pathogenic
7 c.1009+2T>A MH2 (Nevidomskyte et al., 2017) 1 Pathogenic
8 c.1045G>C p.Ala349Pro MH2 (van de Laar et al., 2012) 1 Likely pathogenic
8 c.1080dupT p.Glu361* MH2 Current study 1 Pathogenic
8 c.1081G> T p.Glu361* MH2 (van de Laar et al., 2012) 1 Pathogenic
8 c.1091A>G p.Tyr364Cys MH2 Current study 1 Likely pathogenic
8 c.1102C> T p.Arg368* MH2 (Aubart et al., 2014), Current
study
2 Pathogenic
8 c.1141G>C p.Gly381Arg MH2 Current study 1 Likely pathogenic
9 c.1155-2A>G MH2 (Campens et al., 2015) 1 Pathogenic
9 c.1170_1179del p.Ser391Alafs*7 MH2 (Wischmeijer et al., 2013) 1 Pathogenic
9 c.1179_1180dupC p.Cys394Leufs*4 MH2 (Aubart et al., 2014) 1 Pathogenic
9 c.1185G>C p.Trp395Cys MH2 Current study 1 VUS
9 c.1199T>C p.Leu400Pro MH2 Current study 1 VUS
9 c.1208C> T p.Pro403Leu MH2 (Martens et al., 2013) 1 Likely pathogenic
9 c.1222G>C p.Asp408His MH2 Current study 1 Likely pathogenic
9 c.1224C>A p.Asp408Glu MH2 Current study 1 Likely pathogenic
9 c.1243G>C p.Gly415Arg MH2 Current study 1 Likely pathogenic
9 c.1247C> T p.Ser416Phe MH2 Current study 1 Likely pathogenic
9 c.1259G>A p.Arg420His MH2 (Proost et al., 2015) 1 VUS
9 c.1265C> T p.Ser422Phe MH2 Current study 1 Likely pathogenic
9 c.1267A>G p.Ser423Gly MH2 (Aubart et al., 2014) 1 Likely pathogenic
9 c.1268G>A p.Ser423Asn MH2 Current study 1 Likely pathogenic
9 c.1274C> T p.Ser425Phe MH2 Current study 1 VUS
Deletion from exon 2 onwards: Chr2.hg19:
g.(67,408,242)_(67,603,013)del
(Hilhorst-Hofstee et al.,
2013)
1 Pathogenic
Deletion 15q22.33 Current study 1 Pathogenic
Mutations identified in this study are indicated in bold.
of this condition. Mouse models, like Fbn1+/C1039G, have significantly
changed our understanding of disease pathogenesis. It has been shown
that altered TGF-𝛽 signaling plays an important role in the lung, valve,
skeletalmuscle, and aortic pathology of fibrillin-1-deficientmice (Cohn
et al., 2007; Habashi et al., 2006; Neptune et al., 2003; Ng et al., 2004),
indicating that fibrillin-1 is not only a structural component of the ECM
but also a key regulator of TGF-𝛽 signaling (Dallas, Miyazono, Skerry,
Mundy, & Bonewald, 1995; Isogai et al., 2003). This new hypothesis
was confirmed by a key experiment in which the mutant phenotype
in fibrillin-1-deficient mice could be attenuated by the administration
of TGF-𝛽- neutralizing antibodies (Cohn et al., 2007; Habashi et al.,
2006; Neptune et al., 2003; Ng et al., 2004). Shortly after this, the
central role of TGF-𝛽 dysregulation was proven by the identification
of mutations in the TGFBR1 and TGFBR2 genes as the cause of LDS.
The effect of these mutations on the TGF-𝛽 pathway is, however,
complex as heterozygous loss-of-function mutations associate with
paradoxical activation of TGF-𝛽 signaling, which was demonstrated by
increased phosphorylation of Smad proteins and increased output of
TGF-𝛽-driven genes.
3.1 TGF-𝜷 pathway
TGF-𝛽 is the prototype of a family of secreted polypeptide growth
factors essential in development, differentiation, cell growth,
migration, apoptosis, and ECM production (Derynck & Akhurst,
2007; Massague, Blain, & Lo, 2000). In humans, three TGF-𝛽 ligand
isoforms exist, TGF-𝛽1, TGF-𝛽2, and TGF-𝛽3, encoded by the TGFB1,
TGFB2, and TGFB3 genes, respectively. TGF-𝛽 is secreted from cells
as part of a large latent complex, that consists of the mature TGF-𝛽
cytokine, a dimer of its processed amino terminal propeptide (LAP)
and one of three latent TGF𝛽 binding protein-isoforms (LTBP1, 3,
or 4). The latter binds to ECM components such as fibronectin or
microfibrils composed of fibrillin-1. Upon release from this complex,
TGF-𝛽 binds to the type II TGF-𝛽 receptor subunit (TGF𝛽R2), which
alters its conformation and phosphorylates the type I TGF-𝛽 receptor
subunit (TGF𝛽R1), also known as activin receptor-like kinase 5 (ALK5).
In the canonical pathway, TGF𝛽RI then phosphorylates SMAD2
and SMAD3 proteins that transmit the TGF𝛽 signal to the nucleus
upon association with SMAD4. SMADs are transcription factors that
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TABLE 2 Previously described and novel TGFB2 genemutations
Exon c-Notation p-Notation Domain Reference
Times
reported Effect
1 c.236A> T p.Gln79Leu LAP Current study 1 Likely pathogenic
1 c.244G> T p.Ala82Ser LAP Current study 1 VUS
1 c.274G> T p.Glu92* LAP Current study 1 Pathogenic
1 c.294_308delCTACGCCAA
GGAGGT
p.Ala100_Tyr104del LAP (Lindsay et al., 2012) 1 Likely pathogenic
1 c.297>A p.Tyr99* LAP (Lindsay et al., 2012) 1 Pathogenic
1 c.304G> T p.Glu102* LAP (Boileau et al., 2012) 1 Pathogenic
1 c.305_307delAGG p.Glu102del LAP Current study 1 Likely pathogenic
3 c.475C> T p.Arg159* LAP (Renard et al., 2013),
Current study
3 Pathogenic
3 c.518_519 insT p.Lys174Glufs*18 LAP Current study 1 Pathogenic
3 c.577C> T p.Arg193Trp LAP (Campens et al., 2015),
Current study
2 Likely pathogenic
4 c.673G> T p.Glu225* LAP Current study 1 Pathogenic
5 c.687C>A p.Cys229* LAP (Boileau et al., 2012) 1 Pathogenic
5 c.839-1G>A p.Gly280Aspfs*41 LAP (Ritelli et al., 2014) 1 Pathogenic
6 c.873_888dup p.Asn297* LAP (Boileau et al., 2012) 1 Pathogenic
6 c.979C> T p.Arg327Trp RKKR
motif
(Lindsay et al., 2012), (Renard
et al., 2013), (Schubert
et al., 2016)
3 Pathogenic
6 c.980G>A p.Arg327Gln RKKR
motif
(Renard et al., 2013),
(Campens et al., 2015),
Current study
5 Pathogenic
6 c.988C> T p.Arg330Cys RKKR
motif
(Lindsay et al., 2012),
(Campens et al., 2015),
Current study
4 Pathogenic
6 c.1000delG p.Ala334Arg*fs25 Cytokine Current study 1 Pathogenic
7 c.1021_1025delTACAA p.Tyr341Cysfs*25 Cytokine (Boileau et al., 2012) 1 Pathogenic
7 c.1042C> T p.Arg348Cys Cytokine (Gago-Diaz et al., 2014),
Current study
2 Likely pathogenic
7 c.1097C>A p.Pro366His Cytokine (Lindsay et al., 2012) 1 Likely pathogenic
7 c.1106_1110delACAAT p.Tyr369Cysfs*26 Cytokine (Lindsay et al., 2012) 1 Pathogenic
7 c.1125delT p.Gly376Glufs*17 Cytokine (Renard et al., 2013) 1 Pathogenic
7 c.1165dupA p.Ser389Lysfs*8 Cytokine (Leutermann et al., 2014) 1 Pathogenic
7 c.1170+1G>A Cytokine Current study 1 Pathogenic
8 c.1234G>C p.Asp412His Cytokine Current study 1 VUS
Entire gene Chr1.hg19: g.(215,588,712)_(222,145,072)del (Lindsay et al., 2012) 1 Pathogenic
Entire gene Chr1.hg19:g.(216,672,181)_(220,202,575)del (Lindsay et al., 2012) 1 Pathogenic
Entire gene Chr1.hg19: g.(214,271,966)_(219,506,825)del (Fontana et al., 2014) 1 Pathogenic
Entire gene Chr1.hg19:g.(215,713,272)_(218,899,968)del Current study 1 Pathogenic
Mutations identified in this study are indicated in bold.
partner with other factors that drive TGF𝛽-mediated gene transcrip-
tion (Derynck & Zhang, 1996; Feng & Derynck, 2005; Massague et al.,
2005; Zhang, 2009). Alternatively, ligand-activated TGF𝛽 receptors
can also initiate non-canonical signaling cascades, including RhoA and
the mitogen-activated protein kinases ERK, JNK, and p38 (Derynck &
Zhang, 2003; Lee et al., 2007; Yamashita et al., 2008).
Oneof themost unambiguous indications thatTGF-𝛽 signalingplays
amajor role in aneurysmpathogenesiswasprovidedby the finding that
TGFBR1/2 mutations result in LDS. Aortic wall tissue of TGFBR1 or 2
mutant patients showed increased nuclear accumulation of phospho-
rylated SMAD2 (pSMAD2) and enhanced expression of TGF-𝛽 driven
gene products such as connective tissue growth factor (CTGF), illus-
trating enhanced TGF-𝛽 signaling. The latter is paradoxical as most of
the TGFBR1 or 2 mutations are predicted to lead to a decrease of the
serine-threonine kinase activity of the receptor (Loeys et al., 2005).
An analogous observation was made in medial vascular smooth mus-
cle cells (VSMC) of patients with a SMAD3mutation (van de Laar et al.,
2011). Finally, in accordance with the findings for SMAD3, increased
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TABLE 3 Previously described and novel TGFB3 and SMAD2 genemutations
Gene Exon c-notation p-notation Domain Reference
Times
reported Effect
TGFB3 1 c.106A> T p.Lys36* LAP Current study 1 Pathogenic
TGFB3 2 c.437delT p.Leu146Hisfs*68 LAP Current study 1 Pathogenic
TGFB3 4 c.704delA p.Asn235Metfs*11 LAP (Bertoli-Avella et al., 2015) 1 Pathogenic
TGFB3 4 c.754+2T>C p.Glu216_Lys251del LAP (Bertoli-Avella et al., 2015) 1 Pathogenic
TGFB3 5 c.787G>C p.Asp263His LAP (Bertoli-Avella et al., 2015), Current study 3 Likely pathogenic
TGFB3 5 c.796C> T p.Arg266Cys LAP Current study 1 VUS
TGFB3 5 c.898C> T p.Arg300Trp RKKRmotif (Bertoli-Avella et al., 2015), Current study 5 Pathogenic
TGFB3 5 c.899G>A p.Arg300Gln RKKRmotif (Matyas et al., 2014), Current study 2 Pathogenic
TGFB3 5 c.898C>G p.Arg300Gly RKKRmotif (Kuechler et al., 2015) 1 Likely pathogenic
TGFB3 6 c.965T>C p.Ile322Thr Cytokine (Bertoli-Avella et al., 2015) 1 Likely pathogenic
TGFB3 6 c.979G> T p.Asp327Tyr Cytokine Current study 1 Likely pathogenic
TGFB3 6 c.1095C>A p.Tyr365* Cytokine (Bertoli-Avella et al., 2015) 1 Pathogenic
TGFB3 7 c.1157delT p.Leu386Argfs*21 Cytokine (Bertoli-Avella et al., 2015) 1 Pathogenic
TGFB3 7 c.1202T>C p.Leu401Pro Cytokine (Bertoli-Avella et al., 2015), Current study 2 Likely pathogenic
TGFB3 7 c.1226G>A p.Cys409Tyr Cytokine (Rienhoff et al., 2013) 1 Pathogenic
SMAD2 8 c.954T>A p.Asn318Lys MH2 Current study 1 Likely pathogenic
SMAD2 9 c.1082A>C p.Asn361Thr MH2 Current study 1 Likely pathogenic
SMAD2 10 c.1163A>G p.Gln388Arg MH2 (Micha et al., 2015) 1 Likely pathogenic
SMAD2 10 c.1190C>A p.Ser397Tyr MH2 Current study 1 Likely pathogenic
SMAD2 11 c.1346T>C p.Leu449Ser MH2 (Micha et al., 2015) 1 Likely pathogenic
SMAD2 11 c.1369G>A p.Gly457Arg MH2 (Micha et al., 2015) 1 Likely pathogenic
SMAD2 11 c.1400C> T p.Ser467Leu MH2 Current study 1 VUS
Mutations identified in this study are indicated in bold.
pSMAD2 and CTGF expression was observed in the aortic media of
patients with either loss-of-function TGFB2 or TGFB3 mutations, fur-
ther confirming the paradoxical observation of increased TGF-𝛽 signal-
ing in vivo (Bertoli-Avella et al., 2015; Lindsay et al., 2012).
In addition to increased expression of pSMAD2 and TGF-𝛽-driven
gene products, alternative expression of TGF𝛽-ligands is observed in
LDS patients as well. In human TGFB2 or TGFB3-deficient aortas,
an increase in TGFB1 expression was observed (Bertoli-Avella et al.,
2015; Lindsay et al., 2012). An analogous observation was made in
aneurysmal aortic media of SMAD3mutation positive patients (van de
Laar et al., 2011). Aortic wall tissue of these patients also revealed
an increase in cytoplasmic and nuclear total SMAD3 immunostain-
ing, indicating that other compensatory mechanisms lead to further
dysregulation of the pathway (van de Laar et al., 2011). TGFB2 muta-
tion positive patients showed, besides an increase in TGFB1, also an
enhanced expression of TGFB2 in their aortic wall tissue (Boileau et al.,
2012). AlthoughTGFB2mutations arepredicted to result in haploinsuf-
ficiency, the exactmechanisms on how loss-of-functionmutations lead
to a paradoxical activation of TGF-𝛽 signaling remain elusive.
Different hypotheses have arisen to address this issue but further
experimental validation is mandatory. The first hypothesis states
that a potential cell-autonomous mechanism results in upregulation
of TGF-𝛽 signaling (Lindsay & Dietz, 2011). TGF-𝛽 ligand can acti-
vate both the canonical and non-canonical pathway. By a negative
feedback loop, the canonical pathway can regulate TGF-𝛽 pathway
activity. Mutations in LDS genes (TGFBR1/2, SMAD3, TGFB2/3) cause
a decrease in canonical signaling hereby downregulating the feedback
inhibition in order to restore the canonical signaling pathway. This will
result in increased ligand expression and excessive activation of the
non-canonical signaling pathway. Further supporting evidence for the
contribution of non-canonical signaling came from the observation
that treatment with a specific ERK inhibitor, RDEA119, abrogates
pathological aortic root growth in an MFS mouse model hereby
rescuing the aortic aneurysm phenotype (Holm et al., 2011; Habashi
et al., 2011). Secondly, as shown by increased expression of TGFB1,
both in TGFB2-deficient patients and mice, a shift in the use of specific
TGF-𝛽 cytokine isoforms might contribute to the upregulation of the
TGF-𝛽 cascade (Lindsay et al., 2012). Thirdly, a non-cell autonomous
effect (paracrine) offers an alternative explanation for the observed
increased TGFB1 expression and concomitant enhanced TGF-𝛽 signal-
ing. The VSMC of the thoracic aorta have different embryonic origins:
the cells of the ascending aorta are derived from the second heart
field and cardiac neural crest, whereas the cells in the descending
aorta originate from the somatic mesoderm (proximal descending
aorta) or splanchnic mesoderm (distal descending aorta) (Majesky,
2007). Aneurysms can occur throughout the aorta, implicating that
there is not a common origin for all VSMCs at sites prone to aneurysm
formation. However, aneurysm formation always occurs at locations
where cells of divergent origins can interact (at the transition regions)
(Gallo et al., 2014; Lindsay & Dietz, 2011). Because cells from distinct
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F IGURE 1 Schematic representation of the SMAD2 and SMAD3 gene with their protein coding domains. Boxes represent exons 1–11 and 1–9,
respectively. On the left side of the schematic are the previously reported mutations, whereas on the right side mutations identified in this study
are described. For SMAD2, the first depicted exon is exon 2 because exon 1 is 5′UTR. Mutations are annotated at the protein level, with exception
of splice site mutations (reference transcript: NM_005901.5 andNM_005902.3 for SMAD3)
origins respond in different ways to TGF-𝛽 stimulation, it is likely
that cells of one lineage are more prone to perturbed TGF-𝛽 signaling
compared to cells of another origin (Topouzis & Majesky, 1996). Cell
types that are more sensitive towards heterozygous LDS mutations
might attempt to compensate for the initial loss in TGF-𝛽 signaling
by secreting excessive amounts of TGF-𝛽 ligand in their direct envi-
ronment, leading to overdrive of TGF-𝛽 signaling in neighboring cells
which are intrinsically less vulnerable to LDS mutations (Gallo et al.,
2014). Finally, since increased expression of pSMAD2 is observed in
the aortic media of LDS patients, this might indicate that other TGF-𝛽
related pathways such as angiotensin II or activin signaling cascades
are involved as well (Bernard, 2004; Rodriguez-Vita et al., 2005).
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F IGURE 2 Schematic representation of the TGFB2 and TGFB3 gene with their protein coding domains. Boxes represent exons 1–8 and 1–7,
respectively. On the left side of the schematic are the previously reported mutations, whereas on the right side mutations identified in this study
are described.Mutations are annotated at the protein level (reference transcript: NM_001135599.2 for TGFB2 andNM_003239.3 for TGFB3)
3.2 Mousemodels
For SMAD3, TGFB2, and TGFB3, multiple mouse models have been
developed through the years confirming the hypotheses about the
molecular and cellular mechanisms underlying LDS pathogenesis.
Mouse models for SMAD2 have also been developed but Smad2
knockout mice embryos die before E8,5, due to defective egg cylinder
elongation and germ layer formation, which entangles aortic size
examination (Waldrip, Bikoff, Hoodless, Wrana, & Robertson, 1998;
Weinstein et al., 1998).
Different Smad3 mouse models initially confirmed the importance
of SMAD3 and the TGF-𝛽 pathway for cartilage integrity. Homozygous
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TABLE 4 Pathogenic variants in SMAD2, SMAD3, TGFB2, and TGFB3
present in ExAC
Gene Variant (p-notation) Times in ExAC
SMAD2 p.Gln388Arg 1/121108
SMAD3 p.Arg420His 1/120914
TGFB2 p.Arg193Trp 1/121376
TGFB3 p.Ile322Thr 1/121368
p.Asp327Tyr 1/121378
mutant mice in which Smad3 exon 8 is targeted (Smad3ex8/ex8) develop
progressive degenerative cartilage resembling human osteoarthritis
(Yang et al., 1999). Additionally, Smad3 knock-out mice (Smad3−/−)
show phenotypes similar to human osteoarthritis (Li et al., 2009).
However, initially, these mouse models were not reported to develop
a vascular phenotype (Bonniaud et al., 2004; Li et al., 2009). After
identification of SMAD3 as an aortic aneurysm disease causing gene,
the vascular phenotype of the Smad3 knock-out mice was studied in
more detail (Ye et al., 2013). Necropsy of the Smad3−/− mice revealed
that the majority died from a ruptured aneurysm. Additionally, ultra-
sound imaging of these mutant mice revealed progressive aortic root
and ascending aortic dilation as early as 2months.
Sanford et al reported that Tgfb2-null mice died shortly after birth
and had small, thin walled ascending aortas in addition to other
developmental defects involving different organ systems (Sanford
et al., 1997). In a later study, Bartram et al. (2001) also observed that
Tgfb2-null mice die during gestation due to congenital heart disease
anddisplay aortic anomalies. Therefore, Lindsay et al. studied the Tgfb2
heterozygous knockout mouse model to study aneurysm formation in
more detail. Tgfb2+/−mice showeddilatations of the aortic annulus and
aortic root, a pattern similar to that of LDS and MFS patients (Loeys
et al., 2005; Mc Kusick, 1955), confirming that loss-of-function of one
Tgfb2 allele is sufficient to cause aortic root aneurysm. As Western
blot of Tgfb2+/− mouse aortas showed a similar increase in phospho-
rylation of Smad2/3 and Erk1/2, recapitulating the observations in the
human aorta, it can be concluded that increased activation of TGF-𝛽
signaling underlies the observed phenotype (Lindsay et al., 2012).
Besides Tgfb2+/- mice, the aortas of double-heterozygous knock-out
mice, Tgfb2+/−; Fbn1C+/C1039G, were examined as well. The aortic root
dimensions of Tgfb2+/−; Fbn1C+/C1039G were significantly increased
compared with the wild-type mice at 2 and 4 months of age. Also
elastic fiber fragmentation, higher collagen deposition and increased
nuclear accumulation of pSmad2 in the aortic media were observed.
Tgfb1mRNA levels in the proximal aorta of Tgfb2+/−; Fbn1+/C1039Gmice
at 2 months of age were elevated, which is similar to the observations
in human. This is again underlining the paradoxical TGF-𝛽 pathway
activation and stressing the complex pathogenesis that goes together
with TGF-𝛽 dysregulation.
In 1995, both Proetzel et al. (1995) and Kaartinen et al. (1995)
generated, independently, a Tgfb3 null mutant mouse model. Homozy-
gous Tgfb3 knockout mice died within 20–24 hr of birth displaying
defective palatogenesis but no other concomitant craniofacial or
growth abnormalities. Additionally, abnormal pulmonary development
was observed. Azhar et al. (2003) described irregularities in the
curvature and position of the aortic arches in Tgfb3 knockout mice,
but no major cardiac defects have been reported. More recently,
Doetschman et al. (2012) developed Tgfb3 conditional knockout mice
that died at birth from cleft palate defects, similar to Tgfb3−/− mice,
but there was no record of cardiovascular abnormalities in these mice.
Further evaluation of the aortic sizes of Tgfb3 conditional knockout or
haploinsufficient mice definitely offer some interesting and necessary
research prospects.
4 CLINICAL AND DIAGNOSTIC
RELEVANCE
The most important clinical finding in LDS patients is dilatation of the
aortic root at the level of the sinuses of Valsalva, a feature that nearly
all LDS patients will develop ultimately. Aneurysms of the ascending
or descending aorta are less frequently observed. Dissection and rup-
ture of these aortic aneurysms tend to occur at a younger age and at
smaller diameters in LDS patients compared to MFS patients (Loeys
et al., 2006). The aortic phenotype in patients with SMAD3 mutations
is very similar to TGFBR1/2 patients, whereas TGFB2 and TGFB3 car-
diovascular features tend to be milder, although severe aortic presen-
tation at young age has also been observed. Non-penetrance seems
more common in TGFB2/3 families. Using CT or MRI, 3D reconstruc-
tion of images from the head to pelvis is needed to identify arterial
tortuosity, present in most individuals with a TGFBR1/2, TGFB2, or
SMAD3mutation, and aneurysms in the rest of the arterial tree. This is
F IGURE 3 Frequencies of the different types of SMAD2, SMAD3, TGFB2, and TGFB3mutations identified so far
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TABLE 5 Comparison of the clinical manifestations of patients with
SMAD2, SMAD3, TGFB2, and TGFB3mutations
TGFB2 TGFB3 SMAD3 SMAD2
Hypertelorism + + + +
Bifid uvula/cleft palate + + + −
Exotropia + + + ?
Craniosynostosis − − + ?
Cervical spine instability − + + ?
Retrognathia + + + −
Scoliosis + + + +
Club foot + + + −
Osteo-arthritis + + + +
Dural ectasia + ? + +
Pneumothorax + − + +
Hernia + + + +
Dissection at young age + ? + −
Arterial tortuosity + − + +
+ indicates presence of the clinical feature,− indicates absence of the clini-
cal features and a question mark illustrates presence of the clinical feature
is unknown.
essential because aneurysms distant from the aortic root can be easily
overlooked using echocardiography.
Skeletal features in LDS include joint hyperlaxity, scoliosis, arachn-
odactyly, pectus deformity, and club foot, showing some overlap with
those of MFS. Additionally, osteoarthritis and hernia (mostly inguinal)
have been frequently observed in all LDS types (Table 5). Although a
significant overlap exists between the phenotypic characteristics of
SMAD2/3, TGFB2/3 patients and prior TGFBR1/2 reported features,
some differences seem to emerge (Table 5). For example cervical spine
instability has not yet been seen in TGFB2/3 mutations patients, and
craniosynostosis has only been reported once in a SMAD3 patient. For
the first time, we report on cleft palate in patients with TGFB2 muta-
tions. The number of patients with SMAD2 and TGFB3 mutations is
probably too low to draw any significant conclusions so far. For TGFB2
and SMAD3, a detailed summary of the clinical manifestations, both
of the patients previously described in the literature and our newly
reported patients, can be found in Suppl. Tables S2 and S3. For TGFB3
and SMAD2, detailed clinical features of all patients reported so far are
listed in Suppl. Tables S4 and S5.
Although no formal diagnostic criteria have been developed,
genetic testing of the LDS genes should be considered in the following
scenarios: (1) patients with the typical clinical trial of hypertelorism,
cleft palate/bifid uvula and arterial tortuosity/aneurysm; (2) early
onset aortic aneurysm with variable combination of other features
including arachnodactyly, camptodactyly, club feet, craniosynostosis
(all types), blue sclerae, thin skin with atrophic scars, easy bruising,
joint hypermobility, bicuspid aortic valve, patent ductus arteriosus,
atrial and ventricular septum defects; (3) sporadic young probands
with aortic root dilatation/dissection; (4) familieswith autosomal dom-
inant thoracic aortic aneurysms, especially those families with early
onset aortic/arterial dissection, aortic disease beyond the aortic root
(including cerebral arteries); (5) patients with a MS-like phenotype,
especially those without ectopia lentis, but with aortic and skeletal
features not fulfilling the MS diagnostic criteria; (6) patients with
clinical features reminiscent of vascular Ehlers–Danlos syndrome (thin
skin with atrophic scars, easy bruising, joint hypermobility) and normal
type III collagen biochemistry and/or normal COL3A1 genetic testing.
The diagnosis of LDS is established in a proband (by definition a
person without a known family history of LDS), who has a heterozy-
gous pathogenic variant in SMAD2, SMAD3, TGFB2, TGFB3, TGFBR1, or
TGFBR2 and either of the following (MacCarrick et al., 2014): (1) aor-
tic root enlargement (defined as an aortic root z-score greater than or
equal to 2.0) or type A dissection or (2) compatible systemic features
including characteristic craniofacial, skeletal, cutaneous and/or vascu-
lar manifestations found in combination. Special emphasis is given to
arterial tortuosity, prominently including the head and neck vessels,
and to aneurysms or dissections involving medium-to-large muscular
arteries throughout the arterial tree. In the presence of a family his-
tory of documented LDS, the diagnosis can bemade in at-risk relatives
on the basis of molecular genetic testing, even if vascular involvement
or other features are not yet apparent.
5 FUTURE PROSPECTS
The recent identification of SMAD2,3 and TGFB2,3 as disease causing
genes responsible for LDS phenotypes further pinpoints altered TGF-𝛽
signaling as the culprit in aortic aneurysm pathology. As we anticipate
that more genes will cause similar clinical LDS phenotypes, there is a
clear rationale for the development of gene panels. This makes it pos-
sible to screenmultiple candidate genes at one go, taking advantage of
the next-generation sequencing techniques, which are more time and
cost efficient compared with the elaborate Sanger sequencing tech-
nique. As shown by recent studies, this will facilitate the assessment
of an accurate genetic diagnosis for LDS patients hereby surely bene-
fiting patient management (Campens et al., 2015; Proost et al., 2015).
Cardiovascular manifestations of LDS can be managed in a medi-
cal and/or surgical treatment strategy. Since vascular disease is more
aggressive in LDS compared with MFS, prophylactic aortic surgery is
already being recommended at smaller aortic root dimensions of 4.0-
4.5 cm (MacCarrick et al., 2014). In order to reduce aortic wall-shear
stress and eventually aortic dilatation, beta-blockers, such as atenolol,
have been the first-line treatment (Shores, Berger, Murphy, & Pyeritz,
1994). However, since aortic-root tissue of LDS patients shows exces-
sive TGF-𝛽 activation and signaling, therapies that reduce TGF-𝛽 path-
wayactivationoffer attractive therapeutic targets. Indeed, angiotensin
II type 1 receptor blockers, such as losartan, reduce the rate of aortic
root growthby lowering the expression of TGF𝛽 ligands, receptors, and
activators (Everett, Tufro-McReddie, Fisher, & Gomez, 1994; Fukuda
et al., 2000; Habashi et al., 2006; Naito et al., 2004). Although a ran-
domized clinical trial comparing losartan with atenolol did not show
a significant difference in the rate of aortic-root dilatation between
these two treatment groups, the observation that aortic-root z-scores
decrease especially in younger patients advocates to start therapy ear-
lier in the disease course (Lacro et al., 2014). Alternatively, the use of
ERK inhibitors (RDEA119) and angiotensin II type 2 receptor agonists
offer interesting alternative treatment options (Loeys, 2015).
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The full spectrum of phenotypes associated with some genes of
the TGF-𝛽 related vasculopathies, such as FBN1 and TGFBR1/2, has
been described extensively (Arslan-Kirchner et al., 2011; Cook, Carta,
Galatioto, & Ramirez, 2015; Lerner-Ellis et al., 2014; Ramachandra
et al., 2015; Romaniello et al., 2014). For the more recently identified
LDS genes (TGFB2,3 and SMAD2,3), the phenotypic spectrum has not
been fully studied so far. By summarizing the clinical manifestations
of TGFB2,3 and SMAD2,3 mutation patients, this manuscript extends
the spectrum of phenotypes associated with these LDS genes. How-
ever, the screening of larger cohorts of patients with a LDS-like pheno-
type, whether or not using gene panels, will be required to reveal the
full phenotypic spectrum of LDS.
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